Semaglutide was removed from the FDA shortage list in February 2025 and tirzepatide in late 2024, which closed the shortage-based compounding pathway
PP analysis (32 participants in the semaglutide group and 25 participants in the placebo group) showed greater percentage change in adjusted body weight in the semaglutide group compared to the placebo group (mean (s.e.), 18.5% (2.1) versus 1.10 (2.2), respectively) with an adjusted mean difference of 19.6% (95% CI 15.6 to 23.5
The employer freight, measured at a per-member-per-month (PMPM) rate across all covered employees (not just those utilizing the drugs), has steadily increased from $11 PMPM in 2023 to more than $24 PMPM in 2024, and that up from about $1.50 PMPM in 2019
Many people using GLP-1 medication describe renewed energy, steady progress on the scale, and a sense of hope
Delivery Options Delivery options All deliveries are subject to the availability of the product and product sale conditions been met